MedImmune Partners with Wuxi AppTec

AstraZeneca have reinforced their interest in China by entering into a joint venture between their biotechnology arm MedImmune, and Chinese firm WuXi AppTec, which seeks to quicken the development of a new medicine for inflammatory conditions in the country. Under the joint venture, in which the two organisations will have equal ownership, MedImmune’s experimental, fully-human

Continue Reading